FDA approves Replimune's melanoma drug after rejecting it twice

The FDA has approved Replimune's oncolytic viral therapy for advanced melanoma, a decision that arrives at the end of a long and turbulent process in which the drug was rejected in two separate applications and the company's stock swung sharply along the way.

The treatment relies on "oncolytic virus" technology — a genetically modified virus injected directly into a tumor. Therapies of this kind are designed not only to kill tumor cells directly but also to trigger the immune system to join the fight against the cancer.

The approval process was far from a straight line. The FDA had previously rejected the drug twice, both times requesting additional data, creating a difficult stretch for the company both financially and reputationally. Patient advocacy groups voiced concern during that period about delayed access to the treatment.

This latest approval follows additional clinical data the company submitted that ultimately satisfied the regulator. The FDA has tied the approval to completion of a phase 3 confirmatory trial, meaning the company must still provide further evidence for the drug to remain on the market.

Treatment options for advanced melanoma patients remain limited, particularly for those who don't respond to immunotherapy or who relapse after treatment. Every newly approved option for this patient group is regarded as a clinically meaningful development.

For the company, the approval marks a critical financial turning point. For small and mid-sized biotech firms, the approval of a single drug can often determine the company's future; investor confidence and future research funding hinge directly on decisions like this one.

Oncolytic virus technology remains a relatively young but rapidly growing field in cancer treatment. A handful of therapies using this approach have been approved before, but the field is still considered experimental, and each new approval contributes to its broader acceptance.

Patient advocates described the approval as a relief after roughly two years of uncertainty. The experiences of patients who were able to access the treatment through early-access programs during the rejection period played a notable role in advocacy campaigns.

Regulatory experts are studying the case as an example of how the FDA applies data standards to complex biologic therapies. An approval following two rejections illustrates just how difficult the process can be — and how it can still be overcome when additional evidence is presented properly.

Attention now turns to the results of the phase 3 confirmatory trial. A positive outcome would make the drug's approval permanent; a negative one could prompt the FDA to revisit the decision.